Influenza virus-IN-5

Cat. No.: HY-146147: FAQs
Data Sheet Handling Instructions Technical Support

Influenza virus-IN-5 (Compound 5f) is an inhibitor of influenza virus hemagglutinin (HA) with an EC₅₀ of 1 nM against influenza A/H3N2 virus.

For research use only. We do not sell to patients.

Influenza virus-IN-5 Chemical Structure

CAS No. : 2581825-57-0

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Influenza virus-IN-5 (Compound 5f) is an inhibitor of influenza virus hemagglutinin (HA) with an EC₅₀ of 1 nM against influenza A/H3N2 virus^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	EC₅₀	> 25 μM Compound: 5f	Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 E572K mutant expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staini Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 E572K mutant expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staini	[PMID: 31753804]
HeLa	EC₅₀	≥ 21 μM Compound: 5f	Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 D1122N expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.6 by giemsa staining bas Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 D1122N expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.6 by giemsa staining bas	[PMID: 31753804]
HeLa	EC₅₀	0.88 μM Compound: 5f	Inhibition of influenza H3N2 A/X-31 hemagglutinin 3 expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staining based microscopic Inhibition of influenza H3N2 A/X-31 hemagglutinin 3 expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staining based microscopic	[PMID: 31753804]
MDCK	EC₅₀	0.00077 μM Compound: 5f	Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay	[PMID: 31753804]
MDCK	EC₅₀	0.0012 μM Compound: 5f	Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method	[PMID: 31753804]
MDCK	CC₅₀	1.5 μM Compound: 5f	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay	[PMID: 31753804]

Molecular Weight

419.97

Formula

C₂₁H₂₆ClN₃O₂S

CAS No.

2581825-57-0

SMILES

O=C(C1=C(C)C2=C(C=CC(Cl)=C2)N1)NN3C(C(C)SC34CCC(CC4)CC)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Cihan-Üstündağ G, et al. Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones. Bioorg Med Chem. 2020 Jan 1;28(1):115130. [Content Brief]